MT1002 Phase II Study in ACS Patients With PCI
MT1002 Phase II Study in ACS Patients With PCI
Brief Summary:
This is an open-label, sequential-dose escalation/de-escalation trial testing 3 dose levels of MT1002 in patients undergoing PCI due to ACS with NSTEMI.
Detailed Description:
MT1002 is a novel bispecific peptide with properties of a direct thrombin inhibitor and a glycoprotein IIb/IIIa inhibitor.
Three doses of MT1002 will be sequentially tested in cohorts of 6 patients each to achieve target ACT.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Open-Label, Sequential-Dose Escalation/De-escalation Trial
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label, Sequential-Dose Escalation/De-escalation Trial Testing MT1002 in Patients Undergoing PCI Due to Acute Coronary Syndrome With NSTEMI
Actual Study Start Date: December 2, 2020
Estimated Primary Completion Date: May 2022
Estimated Study Completion Date: July 2022
Arm:
- Experimental: MT1002
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Estimated enrolment | 20 |
| Actual Study start date | 02 December 2020 |
| Estimated Study Completion Date | 01 July 2022 |